Ichnos Sciences signs licensing pact with Astria Therapeutics for OX40 antagonist monoclonal… EP News Bureau Oct 12, 2023 Astria Therapeutics is granted global rights to develop and commercialise OX40 portfolio, comprised of Telazorlimab and its…
